MicroRNAs as biomarkers and regulators of nonalcoholic fatty liver disease

被引:28
|
作者
Liu, Xiao Lin
Cao, Hai Xia
Fan, Jian Gao [1 ,2 ]
机构
[1] Shanghai Jiao Tong Univ, Sch Med, XinHua Hosp, Dept Gastroenterol, 1665 Kongjiang Rd, Shanghai 200092, Peoples R China
[2] Shanghai Jiao Tong Univ, Sch Med, XinHua Hosp, Ctr Fatty Liver, 1665 Kongjiang Rd, Shanghai 200092, Peoples R China
基金
中国国家自然科学基金;
关键词
biomarkers; microRNAs; nonalcoholic fatty liver disease; pathogenesis; PROINFLAMMATORY CYTOKINE PRODUCTION; DOWN-REGULATION; CIRCULATING MICRORNAS; DIFFERENTIAL EXPRESSION; CHOLESTEROL-METABOLISM; HEPATIC MICRORNAS; UP-REGULATION; ACID; STEATOHEPATITIS; MIR-122;
D O I
10.1111/1751-2980.12408
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Nonalcoholic fatty liver disease (NAFLD) is a complicated disease affected by the interaction of environmental and genetic factors; however, the precise pathogenesis of the disease has not been fully determined. There is a need to better understand the pathogenesis of NAFLD and to identify non-invasive diagnostic modalities. Recent advances in systematic biology and epigenetics have improved our understanding of the genotype-phenotype relationships in NAFLD. MicroRNAs (miRNAs) are important regulators of a wide range of biological processes. MiRNAs are extremely stable and protect from RNAase-mediated degradation in body fluids, making them attractive candidate biomarkers for the early detection of the disease and the monitoring of disease progression. In this review, we summarized the current knowledge on miRNAs as potential biomarkers of NAFLD at different stages and for the prognosis of advanced diseases. Furthermore, we discussed the implications of miRNAs that functioning in lipid metabolism and hepatic steatosis as well as in hepatic inflammation and fibrosis with regard to the pathogenesis of NAFLD.
引用
收藏
页码:708 / 715
页数:8
相关论文
共 50 条
  • [41] Biomarkers in nonalcoholic fatty liver disease-the emperor has no clothes?
    Sanal, Madhusudana Girija
    WORLD JOURNAL OF GASTROENTEROLOGY, 2015, 21 (11) : 3223 - 3231
  • [42] Biomarkers and subtypes of deranged lipid metabolism in nonalcoholic fatty liver disease
    José M Mato
    Cristina Alonso
    Mazen Noureddin
    Shelly C Lu
    World Journal of Gastroenterology, 2019, (24) : 3009 - 3020
  • [43] Biomarkers in nonalcoholic fatty liver disease-the emperor has no clothes?
    Madhusudana Girija Sanal
    World Journal of Gastroenterology, 2015, (11) : 3223 - 3231
  • [44] The Urine Metabolomics Uncovers Key Biomarkers of Nonalcoholic Fatty Liver Disease
    Dong, Shu
    Bian, Yanqin
    Liu, Ping
    Sun, Mingyu
    HEPATOLOGY, 2013, 58 : 490A - 491A
  • [45] Nonalcoholic Fatty Liver Disease: Focus on New Biomarkers and Lifestyle Interventions
    Notarnicola, Maria
    Osella, Alberto Ruben
    Caruso, Maria Gabriella
    Pesole, Pasqua Letizia
    Lippolis, Antonio
    Tutino, Valeria
    Bonfiglio, Caterina
    De Nunzio, Valentina
    Scavo, Maria Principia
    Mirizzi, Antonella
    Franco, Isabella
    Lippolis, Tamara
    D'Alessandro, Rosalba
    Refolo, Maria Grazia
    Messa, Caterina
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2021, 22 (08)
  • [46] NIMBLE 1.2: REPEATABILITY OF MRI BIOMARKERS IN NONALCOHOLIC FATTY LIVER DISEASE
    Fowler, Kathryn
    Venkatesh, Sudhakar K.
    Obuchowski, Nancy
    Middleton, Michael S.
    Chen, Jun
    Pepin, Kay
    Magnuson, Jessica
    Brown, Kathy
    Batakis, Danielle
    Henderson, Walter
    Shankar, Sudha S.
    Heymann, Helen
    Kamphaus, Tania
    Calle, Roberto
    Sanyal, Arun J.
    Loomba, Rohit
    Ehman, Richard L.
    Sirlin, Claude B.
    Sherlock, Sarah
    HEPATOLOGY, 2023, 77 (05) : E152 - E153
  • [47] Performance and limitations of steatosis biomarkers in patients with nonalcoholic fatty liver disease
    Fedchuk, L.
    Nascimbeni, F.
    Pais, R.
    Charlotte, F.
    Housset, C.
    Ratziu, V.
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2014, 40 (10) : 1209 - 1222
  • [48] Nonalcoholic Fatty Liver Disease Is Related to Nonalcoholic Fatty Pancreas Disease
    van Geenen, Erwin-Jan M.
    Smits, Mark M.
    Schreuder, Tim C. M. A.
    van der Peet, Donald L.
    Bloemena, Elisabeth
    Mulder, Chris J. J.
    PANCREAS, 2010, 39 (08) : 1185 - 1190
  • [49] Circulatory microRNAs as potential biomarkers for fatty liver disease: the Rotterdam study
    Zhang, Xiaofang
    Mens, Michelle M. J.
    Abozaid, Yasir J.
    Bos, Daniel
    Darwish Murad, Sarwa
    de Knegt, Robert J.
    Ikram, M. Arfan
    Pan, Qiuwei
    Ghanbari, Mohsen
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2021, 53 (03) : 432 - 442
  • [50] MicroRNAs as regulators, biomarkers and therapeutic targets in liver diseases
    Wang, Xiaolin
    He, Yong
    Mackowiak, Bryan
    Gao, Bin
    GUT, 2021, 70 (04) : 784 - 795